![Ocuphire Pharma, Inc. logo](/logos/OCUP.webp)
Ocuphire Pharma, Inc.
NASDAQ:OCUP
Overview | Financials
Company Name | Ocuphire Pharma, Inc. |
Symbol | OCUP |
Currency | USD |
Price | 2.05 |
Market Cap | 53,144,610 |
Dividend Yield | 0% |
52-week-range | 1.5 - 4.5 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Richard J. Rodgers M.B.A. |
Website | https://www.ocuphire.com |
An error occurred while fetching data.
About Ocuphire Pharma, Inc.
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD